Correction
This article was originally published in The Tan Sheet
Executive Summary
A news brief in the Aug. 31, 2009, issue, "AdvoCare loses verdict to distributors," should have included a comment from an AdvoCare spokeswoman saying the company believes the Badgetts, its former distributors, were terminated appropriately and AdvoCare intends to appeal the jury verdict that went against the firm. "The Tan Sheet" regrets the omission and corrected the brief posted on our Web site (1"The Tan Sheet" Aug. 31, 2009, In Brief)
You may also be interested in...
AdvoCare loses verdict to distributors
The Carollton, Texas-based multi-level marketer of nutritional and skin-care products must pay $1.9 million to former distributors under a Dallas County court jury verdict finding AdvoCare violated Texas deceptive trade practices law. Dallas law firm Kilgore & Kilgore, counsel for plaintiffs Bruce and Teresa Badgett, said Aug. 26 that AdvoCare refused to change its marketing and business structures to "meet the accountability demands of" the Badgetts and then cancelled their distribution agreements. A spokeswoman said the Badgetts were terminated appropriately and AdvoCare intends to appeal the decision. Separately, the firm and competitive swimmer Jessica Hardy filed suit against each other after Hardy failed a performance-enhancing drug test and blamed an AdvoCare supplement (1"The Tan Sheet" Feb. 23, 2009)
Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: